基因编辑+AI双引擎驱动,百奥赛图如何撬动全球数百亿抗体市场?- DoNews专栏

iDoNews
Apr 10

当很多企业还在为靶点内卷、临床高失败率等行业难题苦苦挣扎时,一家中国Biotech用五年时间完成了一场惊艳的蜕变。2025年,百奥赛图迎来“千鼠万抗”计划启动五周年,其2024年业绩报告显示盈利3354万元,成功实现扭亏为盈!总营收达9.8亿元,其中抗体业务营收达到3.18亿元人民币,同比增长80.7%,海外收入占比超过70%,潜在交易里程碑收入突破数百亿元。这一成绩不仅代表百奥赛图发展迈出关键的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10